Celldex Therapeutics (CLDX) Return on Sales [ROS] (2010 - 2026)
Celldex Therapeutics (CLDX) recorded Return on Sales [ROS] of -366468.18% in Q2 2026, down 357720.65 percentage points from -8747.53% a year earlier but up 196431.82 percentage points from the prior quarter.
Celldex Therapeutics (CLDX) Return on Sales [ROS] (2010 - 2026) Analysis & Trends
On a TTM basis, Celldex Therapeutics' Return on Sales [ROS] came in at -206220.25% as of Jun 30, 2026, down 202166.57 percentage points year-over-year; for FY2025, it was -18599.81%, down 15820.92 percentage points from FY2024.
- Annual Return on Sales [ROS] has a five-year change of -17745.75 percentage points (FY2020 to FY2025).
- Across earlier years, Return on Sales [ROS] came in at -2778.89% in FY2024 (-533.62 pp), -2245.27% in FY2023 (+2643.74 pp), -4889.01% in FY2022 (-3357.23 pp) and -1531.78% in FY2021 (-677.72 pp).
- Quarterly Return on Sales [ROS] has ranged from -562900.00% in Q1 2026 to -1152.92% in Q4 2023 over the past five years.
- On a year-over-year basis, Return on Sales [ROS] has declined for five consecutive quarters, with an average year-over-year change of -122436.82 percentage points over the last eight quarters.
- Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 17003.57 percentage points in Q1 2025, against a drop of 553872.81 percentage points in Q1 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at -562900.00% (Q1 2026), -72027.27% (Q4 2025) and -9855.38% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Celldex Therapeutics | 2.48 Bn | 2.48 Bn | - | -366,468.18% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -366,468.18% |
| Mar 31, 2026 | -562,900.00% |
| Dec 31, 2025 | -72,027.27% |
| Sep 30, 2025 | -9,855.38% |
| Jun 30, 2025 | -8,747.53% |
| Mar 31, 2025 | -9,027.19% |
| Dec 31, 2024 | -4,768.26% |
| Sep 30, 2024 | -1,633.53% |
| Jun 30, 2024 | -1,854.16% |
| Mar 31, 2024 | -26,030.77% |
| Dec 31, 2023 | -1,152.92% |
| Sep 30, 2023 | -2,718.46% |
| Jun 30, 2023 | -12,389.93% |
| Mar 31, 2023 | -3,357.91% |
| Dec 31, 2022 | -1,728.77% |
| Sep 30, 2022 | -6,804.91% |
| Jun 30, 2022 | -22,328.83% |
| Mar 31, 2022 | -13,366.09% |
| Dec 31, 2021 | -6,089.82% |
| Sep 30, 2021 | -13,610.46% |
Celldex Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLDX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "CLDX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLDX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();